Q1 2025 Bavarian Nordic A/S Earnings Call Transcript
Key Points
- Bavarian Nordic AS (BVNKF) reported a strong start to the year with a 62% growth in revenue, reaching almost 1.4 billion krona.
- The company achieved an EBITDA margin of 31%, indicating strong profitability.
- Successful launch and approval of the chikungunya vaccine, Bunya, in the US, Europe, and the UK.
- Strong performance in the travel health segment, with significant market share gains in rabies and tick-borne encephalitis (TBE) vaccines.
- Secured a new order from the US government worth $144 million, enhancing revenue stability for 2026.
- The company is slightly short of the bottom end of the guidance for public preparedness, despite strong performance.
- Concerns about potential negative impacts from wholesaler stocking in Germany, which could affect future sales.
- The company faces uncertainties related to potential tariffs and changes in US regulatory policies.
- There is a cautious approach to travel health growth projections, despite strong Q1 performance, due to seasonality and market dynamics.
- The company has not yet sold its priority review voucher, indicating potential delays in realizing cash from this asset.
/- -
Welcome everyone to this Q1 update from the Nordic on a lovely green day.
My name is Rob Johnson from Investor Relations, and today in this conference call we also have Paul Chapin, our CEO, and Henry Y, CFO to give the presentation and comments to All the questions you may have, to the session we have as usual afterwards.
As you may recall last time we had some issues for some analysts and investors having difficulties getting through with questions. If you realize difficulties getting through, please give me a call or send me a text so I can manage to get your questions to management.
If it's not possible to get through.
But before we start this presentation, please note that this announcement includes following statements that involve risks, uncertainties, and other factors, many of which are outside our control, but would cause a results to differ materially from results discussed. For looking statements include statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
